Proxy Materials

Amylyx Pharmaceuticals, Inc. Filed 2024-04-24 Acc 0000950170-24-047244

Documents 1

2025-04-24 DEFA14A Proxy Materials
2024-04-24 ARS Annual Report to Security Holders
2024-04-24 DEFA14A Proxy Materials
2024-04-24 DEF 14A Proxy Statement
2024-04-18 4 Chief Financial Officer acquired 91,180 shares (grant or award)
2024-04-18 4 Co-Chief Executive Officer acquired 179,850 shares (grant or award)
2023-04-27 DEFA14A Proxy Materials

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading amlx-defa14a-2024-additi.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…